To evaluate the short-and long-term effects of 3-adrenergic blockade (metoprolol) as well as the reaction to withdrawal and readministration of metoprolol in severe heart failure, 33 patients (25 men and eight women; mean age, 47.6± 14.0 years) with dilated cardiomyopathy were studied by right and left heart catheterization, right ventricular biopsy, two-dimensional and Doppler echocardiography, and external pulse recordings. Twenty-six of 33 patients survived more than 6 months, and 24 of the 26 patients improved their functional class (from mean 3.3 to 1.8, p<0.0001). These 24 patients were subjected to withdrawal of metoprolol until the number of symptoms increased and deterioration occurred as observed noninvasively (group 1, n=16), whereas the eight patients did not deteriorate during a 12-month period (group 2). During long-term treatment with metoprolol, there was an increase in ejection fraction from 0.24 to 0.42 (p<0.000l), whereas there was a decrease in the left ventricular (LV) end-diastolic dimension (from 7.3 to 6.4 cm, p <0.0001), in the grade of mitral regurgitation (from 1.7 to 0.4, p <0.0001), and in the grade of tricuspid regurgitation (from 0.6 to 0.05, p <0.007). There was a decrease in pulmonary wedge pressure (from 23.8 to 10.7 mm Hg, p<0.0001), LV end-diastolic pressure (from 24.1 to 13.4 mm Hg, p<0.002), and systolic vascular resistance (from 1,782 to 1,499 dynes/sec/cm,p<0.04). There was an increase in systolic blood pressure (from 116 to 132 mm Hg, p<0.003), cardiac index (from 2.17 to 2.58 1/min/m2, p <0.005), and LV stroke work index (from 31 to 65 g m/m2, p<0.0001). During withdrawal of metoprolol, the heart rate and left atrial dimension increased (p <0.0001), whereas ejection fraction decreased (p <0.0001). The 12 (of 16) patients in group 1 who survived the withdrawal period had metoprolol readministered, and subsequently, ejection fraction increased (from 0. 23 33 consecutive patients with idiopathic dilated cardiomyopathy in a treatment regimen with metoprolol in addition to conventional treatment regimen for heart failure. The patients were followed up until February 1987 (Figure 1 ). All patients had experienced at least one episode of heart failure requiring shortterm hospitalization. They were all symptomatic at the start of 3-blocker treatment. Sixteen patients were categorized as New York Heart Association (NYHA) functional Class IV, 15 in functional Class III, and two patients in functional Class II ( Figure  2 ). Improvement or deterioration was assessed in each patient in an unblinded fashion; however, all patients were evaluated by at least two independent cardiologists. In most cases, however, improvement or deterioration was obvious because of the observed dramatic clinical changes.
All patients above 35 years of age had coronary angiography performed that showed normal coronary arteries in all patients except one in whom a 40% stenosis was seen in an obtuse marginal branch. This patient was included in the study because the minor coronary obstruction was not considered to be the probable cause of the diffuse hypokinesia that was found. In addition to the 33 studied patients, the intention was to treat another two patients having diffuse cardiomyopathy. They were, however, excluded because of three-vessel disease. Included were, thus, 25 men and eight women ranging in age from 17 to 65 years (mean, 47.6±+14.0 years). In all patients, acute or chronic myocarditis was excluded by the findings of right ventricular endomyocardial biopsy. In nine of the patients, endomyocardial biopsies were repeated after longterm metoprolol treatment for determination of l3-adrenergic receptor density. In 16 patients, repeated morphometric measurements were performed after long-term metoprolol treatment (data not given here). None of the patients was suspected of alcohol abuse. Concomitant treatment for heart failure is given below. There was an attempt not to change concomitant treatment during the follow-up period because it may complicate interpretation of followup data. Inclusion of study patients was performed between 1979 and 1984. During this period, treatment with vasodilators was relatively rare in our department compared with treatment now. During the study, the following medication (mean+SD) was administered before and at the end of l3-blocker treatment, respectively: digoxin (0.26±+0.03 mg, n=18; 0.26±+ 0.03 mg, n=17), furosemide (140±+-91 mg, n=23; 102+64 mg, n=18), spironolactone (100±32 mg, n=6; 88±25 mg, n=4), captopril (37.5±0 mg, n=2; 37.5+0 mg, n=2), hydralazin (175+87 mg, n=3; 125±87 mg, n=3), and nitroglycerin (80 mg, n=1; 80 mg, n=1). No patient included in the present study had received long-term treatment with inotropic drugs, anthracyclines, or immunosuppressive drugs. Baseline characteristics are given in Tables 1 and 2 for survivors (n=26) and nonsurvivors (n=7). Mean values for the survivors in NYHA functional Class IV (n=9) are shown separately for comparison with nonsurvivors (all functional Class IV).
Study Protocol
An attempt was made to obtain a hemodynamically stable condition during conventional treatment before initiation of 13-blockers, but this was accomplished in only five of the 16 patients of functional Class IV. Subsequently, all patients underwent right and left heart catheterization at rest and right ventricular endomyocardial biopsy; in addition, patients underwent noninvasive investigation by M-mode and two-dimensional echocardiography, pulsed or continuous wave Doppler, phonocardiography, carotid pulse tracing, and apex cardiography. The study was approved by the local Ethical Committee of the Gothenburg University, and participants were informed and gave their consent.
Catheterization
Patients were catheterized in the morning in postabsorptive state. No tranquillizer was routinely given. All medication for heart failure was given 3 hours before the catheterization procedure that included 13-blocker administration at the follow-up catheterization. A Swan-Ganz thermodilution catheter was introduced through the internal jugular vein and positioned in the pulmonary artery, and an artery catheter was inserted through the femoral artery.
Pressures were measured by Statham P23 transducer (Cleveland, Ohio) and stored on tape for subsequent automatic data processing. Cardiac output was determined by the thermodilution technique (Cardiac Output Computer, WTI).
Vascular resistance was expressed as dynes sec±cm5. Systemic resistance was calculated as 80x(mean arterial pressure-right atrial pressure)/ cardiac output. Pulmonary vascular resistance was calculated as 80 x (pulmonary artery pressure -mean pulmonary capillary wedge pressure)/cardiac output. Left ventricular stroke work index was calculated at 0.0136 x stroke volume indexx(systolic blood pressure -left ventricular end-diastolic pressure) and expressed as g* M/M2. At the end of the metoprolol treatment, 22 patients were recatheterized, whereas noninvasive followup investigations were performed 2 weeks, 1, 3, and 6 months after initiation of treatment in most patients. In some patients, there were additional 9-, 12-, and 18-month follow-up studies. After recatheterization, systematic follow-up by noninvasive investigations was performed before withdrawal of metoprolol and at 2 weeks, 1, 3, 6, 9, and 12 months after medication was withheld. When deterioration was observed, metoprolol was readministered. Deterioration after withdrawal of metoprolol was defined as clinical deterioration by at least one NYHA functional class plus at least two of the following alternatives: 1) decrease of ejection fraction of 0.05 or more, 2) increase of left atrial diameter by 3 mm or more, 3) reappearance or increase in grade of mitral or tricuspid regurgitation, 4) increase of rapid filling wave ratio by 25% or more. When there was no deterioration after 12 months, metoprolol was permanently withdrawn, and these patients had only occasional further follow-up studies. In patients who deteriorated after withdrawal of metoprolol, medication was readministered with a follow-up of [6] [7] [8] [9] [10] [11] [12] months, and the patients were monitored noninvasively at 3-month intervals.
Metoprolol was withdrawn in 24 of 26 patients (mean observation time, 7.7±4.9 months; range, 1-18 months). One patient moved out of the catchment area and was therefore not eligible for withdrawal. One patient who suffered from paroxysmal ventricular tachycardia before metoprolol treatment was free of arrhythmias while on long-term metoprolol treatment and was excluded from withdrawal because of risk of recurrent ventricular tachycardia. Withdrawal was continued until increased symptoms occurred in addition to deterioration of noninvasive hemodynamic variables. Patients were grouped according to results of withdrawal: group 1 (n = 16), those who died or deteriorated within 18 months; and group 2 (n=8), those who did not deteriorate.
Data Analysis and Statistical Methods
Mann-Whitney's nonparametric U test was used for group comparisons. Hemodynamic baseline variables were compared: 1) between those who tolerated metoprolol and survived for more than 6 months and those who did not tolerate metoprolol and died within 3 months or had heart transplantation; 2) between those patients of functional Class IV who died and those who survived. Paired Student's t test was used to evaluate intraindividual changes. Noninvasive follow-up data at varying intervals during long-term treatment with metoprolol were compared with entry variables. A similar analysis was carried out during the withdrawal phase of metoprolol, comparing the corresponding variables before withdrawal. After readministration, the various variables were compared with the corresponding variables before readministration. In a separate analysis, using MannWhitney's nonparametric U test, patients who deteriorated after withdrawal were compared with patients who did not deteriorate.
Invasive hemodynamic data at entry were compared with follow-up data using Student's paired two-tailed t test, and finally, the effect of short-term metoprolol treatment was compared with long-term treatment in the same individuals.
Results

Clinical Findings
Twenty-six of 33 patients survived more than 6 months, and seven died within 3 months (Figure 1) . One patient had heart transplantation but died later from sepsis. Five of the nonsurviving patients did not tolerate oral metoprolol even in small doses (5 mg bid). Two patients initially tolerated a low dose of metoprolol but died during the titration period; they died of right ventricular failure after massive pulmonary embolism that had necessitated the withdrawal of metoprolol. Univariate analyses of hemodynamic variables are given in Table 1 end systole correlated well (r=0.89 and r=0.96 before and after treatment), only measurements at end systole showed a significant decrease (end diastole from 276±78 to 262±80 g, p=NS; end systole from 306+95 to 267±80 g, p=0.0007).
An improvement of diastolic function was evidenced by reduced left atrial dimension and decreased rapid filling wave. An important decrease of mitral regurgitation probably contributed to the reduction of atrial dimension. Also, the degree of tricuspid leakage was reduced after treatment.
The time course of the changes in ejection fraction, left atrial diameter, and rapid filling wave was analyzed. Only minor changes in left atrial size were observed until 3 months of follow-up, and maximum changes were observed after 6 months. Only minor changes in ejection fraction were seen after 1 month, and about 50% of the improvement occurred after 3 months. In contrast, the changes in rapid filling were observed already after 1 month, with only small additional changes during the following 5-12 months. When rapid filling wave ratio in all patients, in whom an apex curve could be obtained, was plotted against pulmonary wedge pressure, it was found that a fall in pulmonary wedge pressure was accompanied by a decrease in rapid filling wave ratio (Figure 4) .
The regression line of the relation between mean
Vcfc and end-systolic wall stress was significantly changed (p<0.01) by metoprolol treatment, and for most patients, this relation was shifted to the left and upward ( Figure 5 ). Withdrawal of metoprolol. After withdrawal of metoprolol in 24 patients, four died ( Figure 1 ). These four patients were in functional Class III before /-blocker treatment, and they had progressed to functional Class II (three patients) and 
years).
All variables but blood pressure, degree of tricuspid regurgitation, and rapid filling wave ratio worsened during the withdrawal period (Table 3) . When the temporary changes in noninvasive variables were followed up during withdrawal of long-term metoprolol treatment, the pattern of effect was reversed compared with the metoprolol treatment period. Ejection fraction decreased within 2 weeks (from 0.41 to 0.37, p<0.01) and remained significantly lower than the baseline level. Left atrial dimension increased slowly (a significant increase by 1.9 mm, p<0.05, was noted 6 months after withdrawal), and the rapid filling wave did not deviate significantly for the whole group during withdrawal, although there was a tendency toward an increase (p=0.067). Patients who deteriorated (group 1) displayed a pattern more obviously congruent to that seen during the long-term metoprolol treatment period than did the whole group and particularly the patients of group 2 ( Figure 6 ). At baseline, before withdrawal of metoprolol, there was a significantly lower ejection fraction ( Figure  6A ) and a larger left atrial dimension ( Figure 6B ) in group 1 than in group 2. An increase in rapid filling wave ratio was a late phenomenon that indicated severe heart failure ( Figure 6C ). Further withdrawal of metoprolol caused an increase or reappearance of mitral and tricuspid regurgitation in some patients.
The patients who died during the withdrawal period all deteriorated at least one NYHA functional class.
In addition, deterioration was seen in the hemodynamic variables. Another three patients were severely decompensated and required hospitalization.
Readministration of metoprolol. Metoprolol was given to all 12 patients in group 1 who survived the This fall in resistance is probably an indirect effect of metoprolol because metoprolol lacks vasodilating properties and because the dose of vasodilators was unchanged between the two measurements. The fall in systemic vascular resistance may be secondary to a decrease in circulating norepinephrine or to a decrease in renin and angiotensin levels secondary to /3-blockade, as could be seen after long-term treatment with /3-blockade in hypertensive patients.25 Systolic blood pressure measured invasively at follow-up increased significantly, whereas the rise in systolic blood pressure measured noninvasively was not significant (Tables 2  and 3 ). The reason for these findings may be that the invasive procedure per se causes sympathetic stimulation in contrast to the less stressful noninvasive procedure. A more vigorous systolic contraction at the follow-up catheterization due to up-regulation of /3-adrenergic receptors26 may result in a higher resting systolic blood pressure. A stronger sympathetic activity may also be reflected in the tendency to higher heart rate at follow-up catheterization compared with follow-up noninvasive investigations.
There is a contrasting effect between short-and long-term administration of metoprolol; the former produces an acute depression of systolic function, and the latter produces a marked improvement of systolic function. These findings are in contrast with the hemodynamic effects observed with shortand long-term administration of vasodilators, although they are in agreement with the improvement after long-term treatment with angiotensin converting enzyme inhibitors. 23 The reason why metoprolol did not change left ventricular filling pressure remains obscure, but the phenomenon may be due to a prolonged filling period and improvement in compliance. Jkram et a127 showed that the decrease in stiffness is constant after short-term administration of acebutalol to patients with dilated cardiomyopathy. This finding may explain a greater ventricular diastolic volume without an increase in filling pressure.28 A decrease in systolic shortening after short-term administration of /3-blockade may therefore not cause a marked fall in stroke volume because the ventricle with a greater end-diastolic volume could produce a similar stroke volume with less systolic shortening.
Among the most important variables discriminating between survivors and nonsurvivors were fractional shortening or ejection fraction, LV ejection time percentage, right atrial mean pressure, systemic blood pressure, and stroke work index. We also used heart function variables that are claimed to be load independent.17 End-systolic wall stress! volume index increased during long-term treatment, indicating an improved systolic function.18 When values for mean Vcf, were plotted against endsystolic wall stress, there was a significant upward shift in the regression line obtained after treatment compared with pretreatment, indicating improved contractility after long-term treatment with metoprolol ( Figure SA) . With treatment, the myocardium could use less of preload reserve, as indicated by an unchanged (left upward shift) or improved (upward shift) relation between Vcf, and wall stress ( Figure SB) .
Absence of an increase in left ventricular filling pressure after short-term administration of metoprolol may explain the lack of increase of dyspnea in most patients during titration of metoprolol. The very early decrease in rapid filling wave ratio, seen already after 1 month of treatment with metoprolol, may indicate a fall in left ventricular end-diastolic pressure. Clinically, we observed that relief of exertional dyspnea during daily activity was an early finding during long-term treatment with metoprolol. This finding was, however, not evaluated systematically in the present study, nor were left ventricular filling pressures measured in the early follow-up period.
How strong is the evidence that improvement was caused by the metoprolol treatment? Spontaneous improvement has been reported to occur in patients with dilated cardiomyopathy.29,30 Regardless of cause, heart failure may worsen or improve progressively. To minimize the influence from spontaneous improvement on the interpretation, only patients who had a stable, poor clinical and hemodynamic condition or had had an exacerbation ongoing for 1 month or more were included. Myocarditis has been proposed as a major cause of dilated cardiomyopathy.31 Chronic active myocarditis was excluded by right ventricular endomyocardial biopsy. However, because some patients may have been in the healing phase after myocarditis at the time of the first biopsy, improvement could be the result of an ongoing healing process.
In 16 of the 24 patients in whom long-term metoprolol treatment was withdrawn, the findings indicate that spontaneous improvement due to healing myocarditis or improvement due to concomitant treatment could not be the only causes of improvement. The slow improvement during the first treatment period, followed by a relatively slow onset of deterioration during the withdrawal period, followed by new improvement during the second treatment period, indicate a cause and effect relation between improvement and metoprolol treatment in these patients. Mode ofAction of Long-term [-Blockade The knowledge of how p-blockers exert their possible beneficial effect is limited. The following mechanisms could be hypothesized.
1) During chronic heart failure, there is a high metabolic load on the myocardium despite a low mechanical output. Recent data indicate limitation of aerobic function of the myocardium with limitation of production of ATP in the mitochondria.32
Short-term P-blockade decreases MVo2 by decreasing heart rate and systolic blood pressure,33 and possibly also by a direct reduction of heat production. All these effects are mediated through ,Breceptor blockade, which is the dominating property of metoprolol. Shortage of energy production in the myocardium may cause a catabolic state with a negative protein synthesis that may be unfavorable because there is a need for compensatory hypertrophy to develop in patients with severe dilatation. Morphometric studies on endomyocardial biopsies before and after long-term metoprolol treatment showed an increase in myocyte diameter (unpublished observation), suggesting that metoprolol may have an advantageous metabolic effect.
2) Chronically elevated levels of circulating catecholamines and a high local release of norepinephrine may worsen heart failure due to direct toxic effects on the myocytes.34
3) There is a marked down-regulation of P3-receptor density in severe heart failure.26,35,36 Downregulation is thought to be a secondary phenomenon to overstimulation of the 3,-adrenergic receptor.
Our group and others have shown that in patients after long-term treatment with metoprolol there is a receptor up-regulation to a level somewhat below the value seen in normal individuals. 26 An increased number of [3-receptors after long-term treatment with metoprolol may explain the increase in exercise capacity, described in some studies after longterm p-blockadel-3,8 because a higher number of receptors may exert a stronger response to sympathetic stimulation during exercise. 26 These results in humans agree well with previous data from animal experiments.37 Because of lack of tissue samples, we have not been able to determine the 3,!/ [32-receptor subpopulations and the relative changes in these. However, Bristow et 25 None of the patients died suddenly during long-term treatment, whereas two of four deaths during the withdrawal period were probably due to arrhythmia according to autopsy. The absence of sudden death during long-term ,8-blockade in the present study is not in accordance with our previous study.3 However, the follow-up in the present study is much shorter, and patients with problems associated with known severe arrhythmia were, with one exception, not included in the study.
The findings in the present study are encouraging, and they support earlier studies of functional improvement after long-term 13-blocker treatment.1,2,4,8,9 The deterioration during 13-blocker withdrawal in most patients and improvement after reinstitution strongly support a treatment effect and exclude spontaneous improvement. Survival data from our previous studies1'4 and from that of Anderson et a19 indicate that long-term metoprolol treatment may prolong survival, but this is not yet proven in a large prospective randomized trial. A large multicenter and international trial is now in progress.
Limitations of the Study
The present study was nonrandomized and unblinded. This may create bias when classifying a patient according to NYHA functional classes. This classification was, however, performed by two independent cardiologists who were not aware of the hemodynamic measurements. Furthermore, there was a good correlation between the changes in NYHA classes and those of the hemodynamic variables. Even though there was only a limited number of patients available for randomization, we believed that the present design was acceptable because patients act as their own controls.
